PMID- 21631893
OWN - NLM
STAT- MEDLINE
DCOM- 20120625
LR  - 20220330
IS  - 1753-0407 (Electronic)
IS  - 1753-0407 (Linking)
VI  - 3
IP  - 4
DP  - 2011 Dec
TI  - Metformin as an antitumor agent in cancer prevention and treatment.
PG  - 320-7
LID - 10.1111/j.1753-0407.2011.00119.x [doi]
AB  - Recent epidemiological investigations conducted in diabetic cohorts and cancer 
      patients have found that metformin users have lower risks for cancer than those 
      using insulin or insulin secretagogues. Studies conducted in various animal tumor 
      models and cancer cell lines have demonstrated that metformin prevents tumor 
      development or inhibits cell proliferation. In addition, a recent clinical trial 
      has shown that short-term use of metformin reduces aberrant crypt foci (ACF) 
      formation in non-diabetic patients with ACF. The antitumor activity of metformin 
      may be mediated through its regulatory effect on hormonal, metabolic, and immune 
      functions. Metformin achieves glycemic control by reducing hepatic glucose 
      production and increasing the muscle intake of glucose, thus lowering levels of 
      circulating glucose and, consequently, insulin. The major molecular targets of 
      metformin are the liver kinase B1 (LKB1)-AMP-activated protein kinase (AMPK) 
      signaling and mammalian target of rapamycin (mTOR) pathways, which are central in 
      the regulation of cellular energy homeostasis and play a crucial role in the 
      control of cell division and cell proliferation. Metformin has been shown to 
      improve endothelial function, decrease inflammatory activity, and regulate immune 
      function. Increasing experimental evidence provides a strong biological rationale 
      for metformin as an antitumor and chemopreventive agent. Metformin is being 
      tested as an adjuvant cancer therapy in clinical settings, and metformin is 
      recommended for all cases of Type 2 diabetes without contraindications. As 
      described in this review, the chemopreventive value of metformin is not 
      restricted to diabetic or obese individuals.
CI  - (c) 2011 Ruijin Hospital, Shanghai Jiaotong University School of Medicine and 
      Blackwell Publishing Asia Pty Ltd.
FAU - Li, Donghui
AU  - Li D
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas MD 
      Anderson Cancer Center, Houston, Texas 77030, USA. dli@mdanderson.org
LA  - eng
GR  - CA106672/CA/NCI NIH HHS/United States
GR  - R01CA098380/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Anticarcinogenic Agents/*pharmacology/therapeutic use
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Humans
MH  - Metformin/*pharmacology/therapeutic use
MH  - Neoplasms/*drug therapy/*prevention & control
EDAT- 2011/06/03 06:00
MHDA- 2012/06/26 06:00
CRDT- 2011/06/03 06:00
PHST- 2011/06/03 06:00 [entrez]
PHST- 2011/06/03 06:00 [pubmed]
PHST- 2012/06/26 06:00 [medline]
AID - 10.1111/j.1753-0407.2011.00119.x [doi]
PST - ppublish
SO  - J Diabetes. 2011 Dec;3(4):320-7. doi: 10.1111/j.1753-0407.2011.00119.x.